Fundación para la Investigación Médica Aplicada (FIMA) / Centro de Investigación Médica Aplicada (CIMA)
Professor Melero’s group has been developing research in the field of Cancer Immunotherapy for more than 15 years. The main topics of research have been related to role of co-stimulatory molecules in cancer immunotherapy, vaccination with DCs and development of novel approaches for immunotherapy comprising the use of gene therapy of cytokine therapy. The interdisciplinary nature of the group and important collaboration with clinicians have resulted in a complex approach to the immune system in tumors, ranging from basic biochemistry of co-stimulatory receptors to the identification of novel pharmaceutical products. Professor Melero’s lab has as well being involved in many collaborations with experts in the field both within Europe and USA. The combination of the broad expertise of the lab and the collaborative attitude have resulted in relevant publications in important journals of the field: PNAS, Cancer Discovery, Clinical Cancer Research.
The Laboratory of Immunology in the Gene Therapy division led by Dr. Melero is a translational research group covering early discovery research to clinical trials sponsored by pharmaceutical industry or by the institution. The major strengths of the group are the analysis of the mechanism of action of immunostimulatory monoclonal antibodies directed to CD137 and B7-H1 (PD-L1). Dr. Melero and his group have extensive preclinical and clinical experience with immunostimulatory monoclonal antibodies and pioneered the work with anti-CD137 mAb. The group is composed of approximately 15 staff members at different levels of training. Regarding gender aspects, the laboratory has a distribution of 5 men and 10 women. (33%/67%).
Staff enrolled in the project
Role and contribution
In PROCROP, FIMA will act as a coordinator of the project and Dissemination and Transfer of knowledge (WP5 & WP6). It is responsible for all aspects of the interface between the project partners and the European Commission. FIMA has appointed two AIPGENE Coordinators, Dr. Gloria González-Aseguinolaza, who will be the focal point for the overall scientific coordination, and Dr. Andrew Solomon, who will manage the administrative and financial content. FIMA is implicated in all the WPs:
- WP1: Analysis of the therapeutic efficacy of the Clinical batch in AIP mice.
- WP2: Elaboration of the clinical protocol. Genetic characterisation of PBGD mutation. Detemination of immune response aginst the vector in patients.
- WP3: Determination of viral shedding, report on the analysis of humoral and cellular immune response against the vector and the PBGD protein, analysis of the oncogenic potential of AAV-AAT-PBGD in animal models.
- WP4: Efficacy analysis ALA and PBG measurements.
- WP5: Management and meeting organization.
- WP6: Dissemination activities.